Growth hormone replacement in patients with a history of malignancy: a review of the literature and best practice for offering treatment

References

• Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 2010;17(3):R141-59
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96(8):2330-40
   PubMed Web of Science ®Google Scholar
• Adan L, Sainte-Rose C, Souberbielle JC, et al. Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation. Med Pediatr Oncol 2000;34(1):14-19
   PubMedGoogle Scholar
• Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003;88(8):3682-9
   PubMedGoogle Scholar
• Murray RD, Shalet SM. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin Endocrinol (Oxf) 2005;62(2):182-8
   PubMedGoogle Scholar
• Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011;7(1):11-24
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006;64(2):115-21
   PubMedGoogle Scholar
• Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997;131(1 Pt 2):S32-6
   PubMed Web of Science ®Google Scholar
• Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995;80(4):1416-22
   PubMedGoogle Scholar
• Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999;50(6):703-13
   PubMedGoogle Scholar
• Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97(2):416-25
   PubMedGoogle Scholar
• Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012;97(2):E213-17
   Google Scholar
• Popovic V, Mattsson AF, Gaillard RC, et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 2010;95(9):4449-54
   PubMedGoogle Scholar
• Hartman ML, Xu R, Crowe BJ, et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 2013;98(3):980-8
   PubMedGoogle Scholar
• Mo D, Hardin DS, Erfurth EM, Melmed S. Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS). Pituitary 2014;17(5):477-85
   PubMedGoogle Scholar
• Harada Y. Pituitary role in the growth of metastasizing MRMT-1 mammary carcinoma in rats. Cancer Res 1976;36(1):18-22
   PubMedGoogle Scholar
• Rose DP, Noonan JJ. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea. Cancer Res 1982;42(1):35-8
   PubMedGoogle Scholar
• Bates P, Fisher R, Ward A, et al. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995;72(5):1189-93
   PubMed Web of Science ®Google Scholar
• Tornell J, Carlsson B, Pohjanen P, et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 1992;43(1-3):237-42
   PubMedGoogle Scholar
• Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996;56(7):1509-11
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363(9418):1346-53
   PubMed Web of Science ®Google Scholar
• Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10(5):421-7
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91(7):620-5
   PubMed Web of Science ®Google Scholar
• Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17(8):421-4
   PubMedGoogle Scholar
• Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A(4):492-7
   PubMedGoogle Scholar
• Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9(4):345-9
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351(9113):1393-6
   PubMed Web of Science ®Google Scholar
• Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62(4):1030-5
   PubMed Web of Science ®Google Scholar
• el Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. Int J Cancer 1994;57(4):491-7
   PubMedGoogle Scholar
• Baxter RC, Butt AJ, Schedlich LJ, Martin JL. Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res 2000;10(Suppl A):S10-11
   Google Scholar
• Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997;272(41):25602-7
   PubMedGoogle Scholar
• Ben-Shlomo A, Sheppard MC, Stephens JM, et al. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011;14(3):284-94
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001;86(7):2935-41
   PubMedGoogle Scholar
• Renehan AG, O’Connell J, O’Halloran D, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35(11-12):712-25
   PubMed Web of Science ®Google Scholar
• Bhansali A, Kochhar R, Chawla YK, et al. Prevalence of colonic polyps is not increased in patients with acromegaly: analysis of 60 patients from India. J Gastroenterol Hepatol 2004;19(3):266-9
   PubMedGoogle Scholar
• Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 1997;47(1):17-22
   PubMed Web of Science ®Google Scholar
• Renehan AG, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85(9):3417-24
   PubMedGoogle Scholar
• Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary 2002;5(1):21-5
   PubMedGoogle Scholar
• Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85(9):3218-21
   PubMedGoogle Scholar
• Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 2007;19(1):23-31
   PubMed Web of Science ®Google Scholar
• Mulder RL, Kremer LC, van Santen HM, et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev 2009;35(7):616-32
   PubMed Web of Science ®Google Scholar
• Schmiegelow M, Lassen S, Poulsen HS, et al. Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol (Oxf) 2000;53(2):191-7
   PubMedGoogle Scholar
• Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2011;29(22):3056-64
   PubMedGoogle Scholar
• Erfurth EM. Update in mortality in GH-treated patients. J Clin Endocrinol Metab 2013;98(11):4219-26
   PubMedGoogle Scholar
• Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85(12):4444-9
   PubMedGoogle Scholar
• Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001;19(2):480-7
   PubMedGoogle Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87(7):3136-41
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91(9):3494-8
   PubMed Web of Science ®Google Scholar
• Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta paediatrica 2006;95(10):1284-90
   PubMedGoogle Scholar
• Woodmansee WW, Zimmermann AG, Child CJ, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol 2013;168(4):565-73
   PubMedGoogle Scholar
• Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 2005;62(6):698-705
   PubMed Web of Science ®Google Scholar
• Mackenzie S, Craven T, Gattamaneni HR, et al. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab 2011;96(9):2756-61
   PubMedGoogle Scholar
• Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2014;99(6):2030-7
   PubMedGoogle Scholar
• Magnavita N, Teofili L, Leone G. Hodgkin’s lymphoma in a cyclist treated with growth hormone. Am J Hematol 1996;52(1):65-6
   PubMedGoogle Scholar
• Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002;360(9329):273-7
   PubMedGoogle Scholar
• Lahm H, Amstad P, Wyniger J, et al. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994;58(3):452-9
   PubMed Web of Science ®Google Scholar
• Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001;86(11):5172-5
   PubMedGoogle Scholar
• Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46(1):75-81
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357(9254):425-31
   PubMed Web of Science ®Google Scholar
• Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012;166(6):1069-77
   PubMedGoogle Scholar
• Child CJ, Zimmermann AG, Woodmansee WW, et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 2011;165(2):217-23
   PubMedGoogle Scholar
• Pekic S, Popovic V. GH therapy and cancer risk in hypopituitarism: what we know from human studies. Eur J Endocrinol 2013;169(5):R89-97
   Google Scholar
• Arnold JR, Arnold DF, Marland A, et al. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf) 2009;70(3):435-8
   PubMedGoogle Scholar
• Chung TT, Drake WM, Evanson J, et al. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol (Oxf) 2005;63(3):274-9
   PubMed Web of Science ®Google Scholar
• Hatrick AG, Boghalo P, Bingham JB, et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 2002;146(6):807-11
   PubMedGoogle Scholar
• Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006;64(5):556-60
   PubMedGoogle Scholar
• Olsson DS, Buchfelder M, Wiendieck K, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol 2012;166(6):1061-8
   PubMedGoogle Scholar
• Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract 2009;15(Suppl 2):1-29
   PubMedGoogle Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(6):1587-609
   PubMed Web of Science ®Google Scholar
• Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72(2):374-81
   PubMedGoogle Scholar
• Koltowska-Haggstrom M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 2009;161(Suppl 1):S51-64
   PubMedGoogle Scholar